Skip to content
Screener

SG&A at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.83B+6.6%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$352.7M-31.4%
AbbVie logo
AbbVieABBV
$3.63B+11.7%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$185M+53.2%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$124M-6.8%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$150.4M+66.0%

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+89.9%
Enterprise value$9.38B+139%
P/E125.9×+113×
P/S+2.1×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
EXPENSES:
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)98,11249,460159,69098,657
Research and development112,92077,370216,265149,187
Selling, general and administrative217,625170,849482,218342,553
Change in fair value of contingent consideration26,41426,414
Amortization of acquired intangible assets22,58534,260
Total expenses477,656297,679918,847590,397
OPERATING (LOSS) INCOME18,35392,978(29,927)106,770

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's SG&A?
Alkermes (ALKS) reported SG&A of $217.63M in Q2 2026.
How has Alkermes's SG&A changed year-over-year?
Alkermes's SG&A increased by 27.4% year-over-year, from $170.85M to $217.63M.
What is the long-term trend for Alkermes's SG&A?
Over 4 years (2021 to 2025), Alkermes's SG&A has grown at a 5.7% compound annual growth rate (CAGR), from $560.98M to $701.52M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Ask your AI about Alkermes's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude